ZA918738B - Prodrugs for beta-lactamase and uses thereof - Google Patents
Prodrugs for beta-lactamase and uses thereofInfo
- Publication number
- ZA918738B ZA918738B ZA918738A ZA918738A ZA918738B ZA 918738 B ZA918738 B ZA 918738B ZA 918738 A ZA918738 A ZA 918738A ZA 918738 A ZA918738 A ZA 918738A ZA 918738 B ZA918738 B ZA 918738B
- Authority
- ZA
- South Africa
- Prior art keywords
- lactamase
- prodrugs
- beta
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
- A61K47/552—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being an antibiotic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nanotechnology (AREA)
- Medical Informatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cephalosporin Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Saccharide Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60966390A | 1990-11-06 | 1990-11-06 | |
US77037191A | 1991-10-08 | 1991-10-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA918738B true ZA918738B (en) | 1992-07-29 |
Family
ID=27086090
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA918738A ZA918738B (en) | 1990-11-06 | 1991-11-04 | Prodrugs for beta-lactamase and uses thereof |
Country Status (8)
Country | Link |
---|---|
EP (2) | EP0742015A1 (ja) |
JP (1) | JPH04264089A (ja) |
AU (1) | AU649275B2 (ja) |
CA (1) | CA2055062A1 (ja) |
FI (1) | FI915210A (ja) |
IE (1) | IE913862A1 (ja) |
MX (1) | MX9101956A (ja) |
ZA (1) | ZA918738B (ja) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994001137A1 (en) * | 1992-07-06 | 1994-01-20 | Hybritech Incorporated | Method for delivery of cytotoxic agents and components thereof |
GB9216759D0 (en) * | 1992-08-07 | 1992-09-23 | Finpael Spa | Process for the production of 7-amino thiazolyl cephalosporins |
DE4236237A1 (de) * | 1992-10-27 | 1994-04-28 | Behringwerke Ag | Prodrugs, ihre Herstellung und Verwendung als Arzneimittel |
GB9314562D0 (en) * | 1993-07-14 | 1993-08-25 | Erba Carlo Spa | Use of cephem derivatives as anti-metastatic agents |
ATE267798T1 (de) * | 1994-01-28 | 2004-06-15 | Univ Kentucky Res Found | Kombinierte wirkstoffe als methode zur gezielten wirkstoff-freisetzung |
CA2177644A1 (en) * | 1995-05-31 | 1996-12-01 | Peter D. Senter | Polymeric prodrugs for beta-lactamase and uses thereof |
JP2002510968A (ja) * | 1997-05-07 | 2002-04-09 | ブリストル−マイヤーズ スクイブ カンパニー | 組換え抗体−酵素融合タンパク質 |
US6159706A (en) * | 1997-12-23 | 2000-12-12 | Newbiotics, Inc. | Application of enzyme prodrugs as anti-infective agents |
WO2000020608A1 (en) * | 1998-10-02 | 2000-04-13 | Genotherapeutics, Inc. | Method of treating prostate cancer with an adenovirus expression vector encoding a prodrug enzyme |
EP1254179A4 (en) | 2000-01-24 | 2005-06-01 | Univ Columbia | IN VIVO SCRAP IMPLEMENTING DIMMERIZATION CHEMICAL INDUCERS |
WO2001083492A1 (en) * | 2000-05-02 | 2001-11-08 | Newbiotics, Inc. | Improved beta-lactam antibiotics |
AU2001293555A1 (en) * | 2000-09-21 | 2002-04-02 | Novation Pharmaceuticals Inc. | Benzoic acid derivatives and uses thereof |
US7083918B2 (en) | 2002-04-24 | 2006-08-01 | The Trustees Of Columbia University In The City Of New York | Bacterial small-molecule three-hybrid system |
US7767792B2 (en) | 2004-02-20 | 2010-08-03 | Ludwig Institute For Cancer Research Ltd. | Antibodies to EGF receptor epitope peptides |
EP1735350B1 (en) * | 2004-04-15 | 2010-08-25 | Genencor International, Inc. | Anti-cea scfv - beta-lactamase constructs (cab molecules) in adept |
CN108338982A (zh) * | 2017-12-27 | 2018-07-31 | 天津国际生物医药联合研究院 | 头孢噻吩钠在抗白血病的药物中的应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1509707A (en) * | 1974-09-20 | 1978-05-04 | Searle & Co | Immunological compounds |
NZ225599A (en) * | 1987-08-04 | 1991-09-25 | Bristol Myers Co | Antibody-enzyme conjugates and combinations with prodrugs for the treatment of tumour cells |
AU633867B2 (en) * | 1989-02-02 | 1993-02-11 | Eli Lilly And Company | Delivery of cytotoxic agents |
GB8907617D0 (en) * | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
-
1991
- 1991-10-30 AU AU86879/91A patent/AU649275B2/en not_active Ceased
- 1991-11-04 ZA ZA918738A patent/ZA918738B/xx unknown
- 1991-11-05 FI FI915210A patent/FI915210A/fi unknown
- 1991-11-05 EP EP96106146A patent/EP0742015A1/en not_active Withdrawn
- 1991-11-05 IE IE386291A patent/IE913862A1/en not_active Application Discontinuation
- 1991-11-05 EP EP19910118822 patent/EP0484870A3/en not_active Withdrawn
- 1991-11-05 JP JP3288962A patent/JPH04264089A/ja active Pending
- 1991-11-06 CA CA002055062A patent/CA2055062A1/en not_active Abandoned
- 1991-11-06 MX MX9101956A patent/MX9101956A/es unknown
Also Published As
Publication number | Publication date |
---|---|
FI915210A (fi) | 1992-05-07 |
FI915210A0 (fi) | 1991-11-05 |
IE913862A1 (en) | 1992-05-22 |
EP0484870A3 (en) | 1992-09-02 |
EP0484870A2 (en) | 1992-05-13 |
EP0742015A1 (en) | 1996-11-13 |
CA2055062A1 (en) | 1992-05-07 |
AU649275B2 (en) | 1994-05-19 |
AU8687991A (en) | 1993-04-01 |
JPH04264089A (ja) | 1992-09-18 |
MX9101956A (es) | 1992-07-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE4190756D2 (en) | Mikrotom | |
DE69125252D1 (en) | Röntgentherapie-simulatormachine | |
TW351991U (en) | Diaper | |
EP0440282A3 (en) | Sensormatrix | |
DE69126781D1 (en) | Fabry-perot-modulator | |
DE69116171D1 (en) | Photo- und biologisch-abbaubare polyethen-copolymere | |
DE69127252D1 (en) | Linearlager | |
ZA918738B (en) | Prodrugs for beta-lactamase and uses thereof | |
DE4092449D2 (de) | Taschenfederkernmatratze | |
DE4191708D2 (en) | Festkoerperlaser | |
GB2243918B (en) | Liquidometer | |
EP0475204A3 (en) | Heteroazepinoid amides | |
EP0458340A3 (en) | Slitterscorer | |
CS262591A3 (en) | Indolonaphthyridines | |
EP0442511A3 (en) | Allen-key | |
EP0444458A3 (en) | Pulsdopplerradar | |
EP0441276A3 (en) | Electrophotoreceptor | |
DE4092685D2 (en) | Mehrkomponenten-kleb- und -werkstoffverarbeitungssystem | |
EP0447954A3 (en) | Spray-station | |
EP0442371A3 (en) | Bisglycosides | |
EP0439820A3 (en) | Vacuumswitch | |
GB9115014D0 (en) | Keto-diacid amides | |
EP0455870A3 (en) | Laboratory-centrifuge | |
AU110900S (en) | Facsimilie | |
DE4191594D2 (en) | Sicherheitsgurtverschluss |